Catalyst Wire Dossier Catalyst Wire Dossier

Nemtabrutinib

nemtabrutinib · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

17 regulatory and trial events tracked for Nemtabrutinib, covering 2024-09-19 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]

See pricing